Cancer Immunotherapy

AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.

Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach.

IACS-9571 (trifluoroacetate) is a potent and selective inhibitor of TRIM24 and BRPF1, with IC₅₀ of 8 nM for TRIM24, and K_d of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

ARG1-IN-1 (Compound 3) is an orally active arginase inhibitor with an IC₅₀ value of 29 nM. ARG1-IN-1 can inhibit serum arginase activity and increase arginine levels in mouse tumor models. ARG1-IN-1 is applicable for tumor research.

(+)-CBI-CDPI1 is an enhanced functional analog of CC-1065. (+)-CBI-CDPI1 is a DNA alkylating agent. (+)-CBI-CDPI1 is an antibody agent conjugates (ADCs) toxin.

Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.

Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity.

PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.

Cbz-Phe-(Alloc)Lys-PAB-PNP is an cleavable linker for antibody-drug conjugates (ADC) design.

Malvidin-3-galactoside (chloride) (Standard) is the analytical standard of Malvidin-3-galactoside (chloride). This product is intended for research and analytical applications. Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function.

SNPB-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate (ADC).

L-Lactic acid-2-¹³C₁ is the ¹³C-labeled L-Lactic acid (HY-Y0479). L-Lactic acid is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid.

ZY-MY-111 is a selective interleukin-4-induced-1 (IL4I1) inhibitor (IC₅₀ = 1.86 μM). ZY-MY-111 competitively occupies the catalytic pocket of IL4I1 and disrupts Trp-AHR signaling in cells. ZY-MY-111 promotes T cell proliferation, enhancing immune responses against the tumor cells. ZY-MY-111 can be used to study colon carcinoma and lymphoma.

Omeprazole (H 16868) magnesium is an orally active H⁺,K⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium also has neuroprotective and antibacterial effects.

Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (K_d ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22⁺ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia.

PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy.

2-Deoxy-D-glucose (Standard) is the analytical standard of 2-Deoxy-D-glucose (HY-13966). This product is intended for research and analytical applications. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexoK_inase.

Atranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC₅₀ values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.

DC4, an ADC cytotoxin, can be used in the synthesis of antibody-drug conjugate (ADC). DC4 can be used for the targeted treatment of cancer.

E7766 disodium is a macrocycle-bridged STING agonist with a K_d of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities.